- Home
- ADV vs SLGL Comparison
ADV vs SLGL Comparison
Compare ADV & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADV | SLGL |
|---|---|---|
| Founded | 1987 | 1997 |
| Country | United States | Israel |
| Employees | 69000 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.6M | 247.1M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | ADV | SLGL |
|---|---|---|
| Price | $0.76 | $72.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $1.83 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 847.1K | 10.2K |
| Earning Date | 03-03-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.63 | $122.71 |
| Revenue Next Year | $0.45 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.49 | $0.40 |
| 52 Week High | $2.11 | $97.97 |
Technical Indicators
Market Signals| Indicator | ADV | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 56.25 | 44.26 |
| Support Level | $0.51 | $71.01 |
| Resistance Level | $0.97 | $96.99 |
| Average True Range (ATR) | 0.08 | 11.38 |
| MACD | 0.02 | -2.39 |
| Stochastic Oscillator | 76.61 | 3.67 |
Price Performance
Historical ComparisonAbout ADV Advantage Solutions Inc.
Advantage Solutions Inc is a omnichannel retail solutions agency in North America, uniquely positioned at the intersection of consumer-packaged goods (CPG) brands and retailers.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.